A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours (Q36615621)

15 August 2017

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours (English)

1 reference

15 August 2017

1 reference

11

J H Beijnen

1 reference

15 August 2017

W S Siegel-Lakhai

1

1 reference

15 August 2017

A S Zandvliet

2

1 reference

15 August 2017

A D R Huitema

3

1 reference

15 August 2017

M M Tibben

4

1 reference

15 August 2017

G Milano

5

1 reference

15 August 2017

V Girre

6

1 reference

15 August 2017

V Diéras

7

1 reference

15 August 2017

A King

8

1 reference

15 August 2017

E Richmond

9

1 reference

15 August 2017

J Wanders

10

1 reference

15 August 2017

J H M Schellens

12

1 reference

15 August 2017

language of work or name

English

0 references

publication date

15 April 2008

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

98

1 reference

15 August 2017

8

1 reference

15 August 2017

1320-1326

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604300

15 August 2017

0 references

cites work

Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Phase II study of E7070 in patients with metastatic melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

An adverse interaction between warfarin and capecitabine: a case report and review of the literature

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spe

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Phenytoin and fluorouracil interaction

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361705

Control of the cell cycle and apoptosis

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604300

A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

12 December 2020

PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression

1 reference

12 December 2020

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients

1 reference

12 December 2020

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients

1 reference

12 December 2020

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

1 reference

12 December 2020

Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients

1 reference

12 December 2020

Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6604300

1 reference

release_32zonji7czaffaqmj7a3ejvx4q

15 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/32zonji7czaffaqmj7a3ejvx4q

24 November 2022

mapped directly with Wikidata item

1 reference

15 August 2017

PubMed publication ID

18414469

1 reference